Dr Paul Bowyer

Dr Paul Bowyer obtained a MSci in chemistry from Imperial College London with an industrial placement at Syngenta (formerly Zeneca Agrochemicals) in formulation design and testing. This was followed by an MRes on the Molecular and Cellular Basis of Infection and a PhD on the N-myristoyltransferase of Plasmodium falciparum within the Division of Cell and Molecular Biology (also at Imperial College London).

His post-doctoral studies (Bogyo Lab, Department of Pathology, Stanford University School of Medicine) were focused on chemical biology and chemical proteomics of both Plasmodium falciparum and Toxoplasma gondii.

Paul returned to the UK working in malaria drug discovery, first as a principal scientist at Pfizer and then at the London School of Hygiene and Tropical Medicine and MRC Technology. In April 2014, Paul joined NIBSC to lead the malaria study area.

His research to date has been at the interface of chemistry and biology focusing on drug discovery and exploiting chemical and proteomic technologies for the study of P. falciparum and T. gondii biology.

At NIBSC, as well as developing standards to assist in harmonisation of P. falciparum biological assays, Paul is investigating the ability to and mechanisms by which the malaria parasite adapts to various external pressures (eg altered blood cells, pressure from the immune system).